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The use of anonymized stored tissue is a 
routine practice in genetic research. Inves-
tigators who utilize stored samples are 
neither required nor able to obtain infor-
med consent before each use. Many genetic 
studies, however, are conducted on specific 
ethnic populations (e.g., Ashkenazi Jews). 
The results in these cases, although indivi-
dually anonymous, are not anonymous with 
respect to the ethnicity of the participants. 
This lack of group anonymity has led to 
concern about the possibility of stigmatiza-
tion and discrimination based on the results 
of the genetic research. In the present study 
we surveyed Jewish individuals about their 
attitudes regarding the practice of using 
stored DNA samples for genetic research. 
Specifically, we were interested in whether 
attitudes about informed consent and will-
ingness to participate in genetics research 
using stored DNA would depend on the 
circumstances in which the material was 
collected (i.e., clinical setting vs. research 
setting) and the characteristics of the dis-
ease or trait under investigation. Overall, 
most respondents reported that written 
informed consent should be required and 
that they would be willing to provide such 
consent. Participants wt!!re most willing to 
provide consent, however, when the sample 
had been collected in a research rather than 
clinical setting. Further, participants were 
more likely to endorse the need for obtain-
ing consent when the sample was collected 
in a clinical setting. Finally, participants 
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were significantly less willing to participate 
in research that examined stereotypical or 
potentially stigmatizing traits as opposed to 
research that examined medical or mental 
illnesses. Am. J. Med. Genet. 00: 000-000, 
2001. © 2001 Wiley-Liss, Inc. 
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INTRODUCTION 
Scientists' ability to evaluate disease susceptibility 
has become increasingly refined over the last two 
decades. In recent years, studies have provided evi-
dence of alterations in some genes that indicate a 
predisposition to breast cancer (BRCAl and BRCA2l. 
These studies suggested that alterations in BRCAl 
and BRCA2 occurred at a significantly higher rate in 
Ashkenazi Jewish individuals (i.e., those of Eastern 
European descent), as compared with the general popu-
lation [Tonin et al., 1996; Hartge et al., 1999]. Many 
Jewish individuals sought to participate in studies to 
confirm those initial findings [Rothenberg, 1997]. This 
was consistent with the community's successful colla-
boration with the researchers of Tay-Sachs disease in 
the 1970s [Kaback et al., 1993; Kaplan, 1998]. 
After the BRCA1 and BRCA2 reports, another group 
of investigators found a significantly higher prevalence 
of a variant in a colorectal cancer susceptibility gene in 
the Jewish population [Woodage et al., 1998]. When 
this was reported in the media, however, some leaders 
of the Jewish community advised Jews to avoid parti-
cipating in further genetics research [Rothenberg and 
Rutkin, 1998]. These advisors seemed to fear the dis-
crimination or stigmatization of Jews as a consequence 
of research identifYing the population as being at 
higher risk for particular diseases [Rothenberg and 
Rutkin, 1998]. 
In August of 1999, the National Bioethics Advisory 
Committee (NBAC) recognized that concerns about 
stigmatization were not unique to any one ethnic 
community [NBAC, 1999]. This report, and others 
[King, 1992], underscored the point that genetics re-
search has implications for families and social groups, 
and that precautions are needed to minimize the social 
risks to susceptible populations. The NBAC report also 
urged caution in research involving the use of stored 
biological materials when samples belong to individuals 
or groups that are "socially or politically marginalized" 
[National Bioethics Advisory Commission, 1999]. Other 
reports have suggested that consultation with these 
groups in the research development or reporting 
phases, although not required by current regulations, 
might help to minimize the social risks [Clayton, 1999]. 
Likewise, the National Institute of Health"s National 
Human Genome Research Institute (NIH) has estab-
lished as a research priority studies of how genetic 
variation might interact with current concepts of race, 
ethnicity, and culture [NIH, 1999]. 
The present report is the first empirical study on the 
attitudes of Jewish individuals toward genetics 
research involving the use of stored biological material 
(DNA). The primary research question was whether 
attitudes about informed consent and willingness to 
participate in genetics research using stored DNA 
would depend upon the circumstances in which the 
material was collected (i.e., clinical settingvs. research 
setting) and the characteristics of the disease under 
investigation. Using hypothetical vignettes we designed 
a survey to test the hypotheses that rates of willingness 
to participate would be lower in the clinical vs. the 
research setting. In addition, we predicted that will-
ingness to participate would be highest for potentially 
preventable medical diseases (e.g., heart disease), as com-
pared with non preventable diseases (e.g., Huntington 
disease) and mental illnesses (e.g., schizophrenia). We 
further expected that willingness to participate would 
be lowest for behavioral traits (e.g., anxiety), particu-
larly those that might be stigmatizing (e.g., frugality). 
Sociodemographic and cultural predictors of willing-
ness to consent were also evaluated. 
MATERIALS AND METHODS 
Participants 
We recruited a group of Jewish men and women age 
18 to 90 years. Introductory letters describing the study 
were mailed to 1,800 individuals with Jewish surnames. 
These individuals were identifi£d from a purchased list 
of individuals with Jewish surnames in the Baltimore-
Washington DC Metropolitan area. Of the 1,800 indivi-
duals to receive introductory letters, 217 (12%) no 
longer resided at the listed address and 200 (11 %) were 
found not to be Jewish. Thus, a total of 1,383 indivi-
duals were eligible to participate in the study. Of the 
1,383 eligible individuals, 801 (58%) refused to partici-
pate in the survey and 308 (22%) could not be reached 
after 10 attempts. Thus, the final sample consisted of 
273 (20%) Jewish individuals who agreed to complete a 
telephone survey. 
Procedures 
Introductory letters were mailed to each of the 1 800 
individuals who were randomly selected from 'the 
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purchased list. The letters described the study and 
mformed potential participants that they would be 
contacted via telephone to participate in a survey. A 
small gift (a telephone message board and marker) was 
included with the introductory mailing. Two-weeks 
after the first mailing, potential participants were con-
tacted to complete a telephone survey. The structured 
survey took about 30-min to complete and was admini-
stered by professional telephone interviewers using a 
computer-assisted telephone interviewing system. 
Description of the Survey 
The survey instrument was designed to evaluate 
attitudes toward genetics research using stored biolo-
gical materials. The central characteristic of the survey 
was the presentation of two hypothetical scenarios. The 
first scenario described a situation in which the parti-
cipant had provided an anonymous blood sample as 
part of a research study to determine how common a 
specific genetic mutation was in the Jewish population. 
Later, a group of researchers requests to use his/her 
blood for another research study on gene alterations 
found in the Jewish community. The second scenario 
was identical to the first except that the initial blood 
sample was provided in a clinical setting (i.e., as part of 
routine medical care) rather than as part of a research 
study. In both scenarios, participants were assured 
that their names could not be linked to the genetic 
information and that the results could not be released 
to insurance companies or employers. 
.After each sc:enario, participants were presented 
Wlth 8 hypothetical studies focusing on a gene related 
to each of the following: 1) a medical illness that can 
sometimes be prevented or treated if found early (e.g., 
heart disease); 2) a medical illness that presently 
cannot be prevented or treated successfully (e.g., 
Huntington disease); 3) a mental illness (e.g., schizo-
ph~enia~; 4) alcoholism; 5) frugality; 6) homosexuality; 
7) mtell1gence; and 8) creativity. 
Outcome Variables 
Belief in the need for informed consent. For 
each of the hypothetical studies above, participants were 
asked to indicate whether they believed that written 
consent should be required before re-using their DNA. 
We calculated separate summary scores (ranging from 0 
to 8) for the research and clinical scenarios by summing 
the total number of affirmative responses for each. 
Willingness to provide informed consent. 
After each scenario, participants were asked whether 
they would be willing to participate in each of the eight 
hypothetical studies described above. We calculated 
separate summary scores (ranging from 0 to 8) for the 
research and clinical scenarios by summing the total 
number of affirmative responses for each. 
Predictor Variables 
Socioclemographics. We assessed the following 
soci~demographic variables: age, education, gender, 
mantal status. 
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Jewish religious identity. Participants were 
asked "How would you describe your religious iden-
tity?". Potential responses were classified as: orthodox, 
conservative, reform, reconstructionist, secular, athe-
ist/agnostic, don't know. 
Jewish cultural identity. Participants were asked 
to rate the strength of their Jewish cultural identity 
using the following scale: not at all strong, moderately 
strong, very strong. In subsequent analyses we divided 
the sample into those who reported that their Jewish 
identity was not at all strong/moderately strong 
(N = 167) vs. very strong (N = 106). 
Concerns regarding anti-Semitism. We asses-
sed concerns about anti-Semitism with the following 
questions: 1) how concerned are you about anti-
Semitism in the United States? and 2) how concerned 
are you about the possibility that genetic information 
about Jews might contribute to anti-Semitism?. These 
questions were answered using a three-point Likert 
scale ranging from 0 (not concerned at all) to 2 (very 
concerned). 
Attitudes toward community consent. We 
assessed attit.udes toward community consent with the 
following items: 1) in a genetics research study focusing 
on the Jewish population, how important do you think 
it is for researchers to consult with members of Jewish 
religious and community organizations before initiat-
ing the study?; 2) how important is it for researchers to 
get approval of Jewish religious and community 
organizations before initiating the study?; 3) how im-
portant is it for you to be informed about any foresee-
able risks to the Jewish community?; 4) how important 
is it for you to be informed about any foreseeable 
benefits to the Jewish community? 
RESULTS 
Sample Characteristics 
Characteristics of the final sample are displayed in 
Table I. Participants were equally divided between 
men and women with a median age of 52. About two-
thirds of the individuals were married and more than 
half had greater than a college education. In terms of 
religious affiliation, all participants were Jewish with 
about 10% reporting that they were orthodox, 28% 
conservative, 41% reform or reeonstructionist, and 20% 
secular, agnostic or atheist. Finally, 39% of the sample 
reported that their Jewish cultural identity was very 
strong. 
Beliefs Regarding the Need for Consent 
For both the research and clinical scenarios described 
in the Methods section, participants were asked 
whether they believed that researchers should obtain 
written consent before using stored DNA in eight 
hypothetical research studies designed to identify genes 
associated with specific illnesses or traits. Figure 1 
shows the proportion of participants who reported that 
consent should be required for each of the specific tests 
for each of the two scenarios. For each specific test, the 
majority of participants (60-75%) believed that consent 
TABLE I. Sociodemographic Characteristics 
Variable 
Age 
Gender 
Marital Status 
Education 
Religious affiliation 
Jewish cultural identity 
Levels 
<40 
::;50 
50+ 
Male 
Female 
Married 
Unmarried 
< College Graduate 
College Graduate 
> College Graduate 
Orthodox 
Conservative 
Reform/Reconstructionist 
No affiliation (secular I 
atheist/ agnostic) 
Not at all strong 
Moderately Strong 
Very Strong 
% 
23 
22 
55 
49 
51 
68 
32 
13 
36 
51 
10 
28 
41 
20 
11 
50 
39 
should be required regardless of whether the DNA was 
collected in a research or clinical setting. 
To compare the research vs. clinical scenario, we 
created composite measures of belief in the need for 
consent by summing the total number of affirmative 
responses for each scenario. Scores on these composites 
could range from 0 (meaning that the participants did 
not believe consent should be required for any of the 
tests) to 8 (meaning that consent should be required for 
each of the illnesses/traits). We compared the compo-
site consent scores for the research scenario (M = 5.1, 
SD = 3.4) to those for the clinical scenario (M = 5. 7, 
SD = 3.3) using a paired t-test. The results of this 
analysis demonstrated an increased belief in the need 
for consent when the samples were collected in a 
clinical as compared to research setting (T(272) = 4.0, 
P < 0.001). Chi-square comparisons of the individual 
tests across scenarios revealed that for each of the eight 
illnesses/traits, participants were more likely to 
endorse the need for consent in the clinical as compared 
to the research scenario (see Fig. 1). 
Willingness to Participate 
For both the clinical and research scenarios, partici-
pants were asked whether they personally would 
consent to having their stored DNA used in these 
studies. Figure 2 shows the proportion of participants 
who reported that they would consent for each of the 
illnesses/traits across the two scenarios. The willing-
ness to consent to further testing was uniformly high 
across both the clinical and research scenarios. There 
was considerable variation, however, in the willingness 
to consent between preventable/unpreventable disor-
ders and those that might be considered stigmatizing. 
To compare willingness to participate across the two 
scenarios, we created composite measures of participa-
tion by summing the affirmative responses in each 
scenario. The results of a paired t-test comparing the 
research to clinical scenario, indicated that partici-
pants were more willing to participate in studies using 
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Fig. 1. Should informed consent be required? 'p < 0.05; "p < 0.01. 
DNA collected in the research setting (M = 6.4, 
SD = 2.3) than the clinical setting (M = 6.1, SD = 2.7) 
(T (272) = 2.5, P = 0.01). Chi-square comparisons across 
the eight illness/traits revealed that willingness to 
participate was higher for the research scenario for 
studies of: untreatable medical illness, treatable med-
ical illness, mental illness, alcoholism, creativity, and 
intelligence. There was no difference across the two 
scenarios in willingness to participate in studies of 
homosexuality and frugality. These two traits had the 
l1~wl\hdll 
IUikl!!:~orrruit 
Cr\'a1lvity 
Uomot-exu~lity 
!oi<Uig<nu 
0 10 JO 
lowest levels of willingness to participate across the two 
scenarios (see Fig. 2). 
Impact of Study Characteristics on Need for 
Consent and Willingness to Participate 
To examine whether characteristics of the illness/ 
traits being studied impacted upon need for consent or 
willingness to provide consent, we divided the illnesses/ 
traits into four categories: physical illness (treatable 
.0 1!0 611 
~• \\'lio Wo..Wco .. rnl 
100 
Fig. 2. Would you consent? +p<O.JO; 'P<0.05; "P<O.Ol. 
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Fig. 3. The impact of test charscteristic on belief that consent is required. F (3,816) (= (5.18; P(= (0.0015. Bars with different letters differ significantly 
(after Bonfcrroni correction). 
and untreatable physical illness), mental/psychiatric 
illness (mental illness, alcoholism), traits (intelligence, 
creativity), and potentially stigmatizing/stereotype 
confirming traits (frugality, homosexuality). We created 
composite scores for each grouping by summing the 
affirmative responses across the two scenarios (see Fig. 
3). Repeated measures ANOVA across the four cate-
gories revealed significant differences in belief in the 
need for consent (F(3,816) = 5.2, P = 0.002). Bonferroni 
adjusted mean comparisons indicated that participants 
believed that consent was more important when testing 
A Ill! 
for stigmatizing traits (M = 2.82, SD = 1.6) than when 
testing for physical illness (M = 2.61, SD = 1. 7) or non-
stigmatizing traits (M= 2.67, SD = 1.7). 
As displayed in Figure 4, analysis using the com-
posite scores on willingness to participate revealed a 
statistically significant difference in willingness to 
participate across the four categories {F(3,816l = 70.0, 
P<O.OOl). Bonferroni corrected mean comparisons 
revealed that participants were significantly less will-
ing to participate in research designed to identify genes 
associated with stigmatizing traits (M = 2.63, SD = 1.61) 
Fig. 4. Impact oftest characteristics on willingness to participate. F (3,816) = 69.98; P < 0.0001. Bars without common letters differ significantly t..Ster 
Bonferroni correction). 
than research to identify genes associated with medical 
illness (M = 3.49, SD = 1.1), mental illness (M = 3.49, 
SD = 1.1) or non-stigmatizingtraits (M = 2.94, SD = 1.6). 
Predictors of Consent and Participation 
In exploratory analyses, we examined sociodemo-
graphic (age, education level, marital status, sex), 
attitudinal (concern about anti-Semitism, belief in 
community consent) and religious (affiliation, Jewish 
cultural identity) variables as potential predictors of 
consent and willingness to participate. The variables 
that predicted consent were age (r=-0.20, P=0.01), 
education level (F(2,270) = 4.63, P = 0.01) and belief in 
community consent (r=0.13, P=0.04). Specifically, 
individuals who were under 50, those with college or 
post-graduate degrees, and those who believed most 
strongly in the need for community consent, reported 
the strongest support for informed consent before the 
use of stored samples (across both scenarios). The only 
variable that predicted willingness to participate, was 
Jewish cultural identity (t(269)=1.94, P=0.05). Spe-
cifically, individuals with a stronger cultural identity 
were more willing to participate across scenarios and 
across illnesses/traits. 
DISCUSSION 
This descriptive study is the first to characterize the 
attitudes of Jews regarding consent for use of stored 
biological samples in different contexts. Overall, most 
respondents reported that they believed that written 
informed consent should be required before reusing 
stored biological samples for genetics research. This 
was particularly true when the sample had been 
acquired for clinical purposes, as compared with a 
research setting. It is important to point out that we 
did not assess belief in the need for verbal consent. It 
is likely that more participants would have endorsed 
the requirement of verbal consent before reuse of the 
sample. An even larger proportion of respondents 
indicated that they would be willing to participate if 
asked. Again, this was especially true for samples taken 
in a research setting, as compared with a clinical sett-
ing. About 90% of respondents reported that they would 
be willing to provide consente for re-use of samples 
collected in a research setting for studies of mental or 
physical disorders. Of course the stated willingness of 
the study subjects to participate in the hypothetical 
research, does not necessarily indicate that actual 
participation would be that high. Previous research 
has demonstrated a relatively poor association between 
stated intentions and actual behavior [Croyle and 
Lerman, 1993]. · 
One of the objectives of this study was to test the 
hypothesis that there would be greater reluctance to 
provide consent for reuse of samples for conditions that 
are potentially more stigmatizing. Contrary to expecta-
tions, we did not find less willingness to participate in 
studies of mental illness or behavioral traits. There was 
a small, but statistically significant, reduction in will-
ingness to participate in studies involving homosexu-
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ality or frugality, however, both of which are potentially 
stigmatizing. We also explored participant character-
istics that might influence attitudes about consent. 
Individuals who were younger and had higher levels of 
education were more likely to believe in the need for 
consent. 
It is important to note that the participants in this 
study represented a self-selected subset of those ap-
proached for the survey (participation rate= 20%). 
This sample was made up of a high proportion of 
older individuals (more than half were above age 50). 
Further, this sample had an unusually high level of 
education (over one half had Masters or Doctoral 
degrees). It is not surprising that highly educated 
individuals might be strongly motivated to respond to 
a survey regarding genetics research. Because educa-
tion level was positively associated with belief in 
the need for informed consent, however, it is possible 
that this survey overestimated concerns about the 
need for informed consent. Similarly, 39% of partici-
pants in this study reported that their Jewish cul-
tural identity was very strong and 52% reported a 
moderately strong Jewish cultural identity. Again, it 
is not surprising that individuals who strongly identify 
as Jewish would be particularly interested in parti-
cipating in a study of attitudes toward genetics 
research in the Jewish community. Because cultural 
identity was positively related to willingness to parti-
cipate in the hypothetical research scenarios, however, 
this survey may have overestimated the wider Jewish 
community's willingness to participate in genetics 
research using stored samples. Clearly, the results of 
this study must be viewed as representing the atti-
tudes of a subset of the Jewish community, rather 
than the Jewish community at large or the general 
population. 
In addition to this potential participation bias, a 
limitation of this study was that we did not provide 
specific information about the advantages and dis-
advantages of obtaining additional written consent 
for re-use of biological specimens. Reports supporting 
the need for additional consent underscore the impor-
tance of individual autonomy in determining specific 
uses of stored samples, as well as the need to mini-
mize the likelihood of stigmatization or discrimina-
tion of particular individuals or groups [Rothenberg 
and Rutkin, 1998; King, 1992]. The desire of some 
participants for additional consent, however, must be 
balanced against the feasibility and costs of re-contact-
ing large numbers of participants, and the likelihood 
that incomplete capture of previous study participants 
can result in biased study results. It is not known 
whether respondents were aware of these issues, or 
whether providing this information would have inftu. 
enced their attitudes about re-consent. Another limita· 
ti,on of this study is that we did not provide information 
about exactly what they had consented to in the 
original research study. Had the original consent been 
broad enough to cover experimental studies for a 
variety of physical illnesses, the need for additional 
consent may not have been as widely endorsed. Also, 
because our scenarios asked about consent for a study 
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on gene alterations in the Jewish population, it is not 
known whether the same results would have been 
obtained for genetics research not specifically targeted 
toward Jews. It will be important in future studies to 
learn how attitudes about consent are influenced when 
additional details about the consent content and 
process are provided. 
Despite these limitations, the present study begins 
to shed light on attitudes about consent for stored 
biological samples among individuals in the Jewish 
community. Although the views of our study respon-
dents may not be representative of this community or 
the general population at large, these results suggest 
that some individuals feel strongly that additional 
written consent should be required for re-use of 
samples. Further, consent for participation in such 
studies may depend, in part, on the specific condition to 
be studied and the context in which the original sample 
was obtained. Although not sufficient to inform policy 
at this stage, these findings do raise questions that can 
be addressed in future studies about the consent 
content and process. Such studies will be valuable in 
the development of policy on genetics research targeted 
at population groups, that may present social implica-
tions for race, ethnicity or culture. 
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